Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FSME-IMMUN Dose-Finding in Children
NCT00161772Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2002
- Modality
- Whole Inactivated Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of FSME-IMMUN in tick-borne encephalitis (TBE) (3 arms), sponsored by Pfizer. Primary endpoint: Seropositivity Rate. Started Mar 2002; status: completed.
02
Drugs
FSME-IMMUN
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on NCT00161772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161772.